Document Detail


Prognostic significance and targeting of HER family in colorectal cancer.
MedLine Citation:
PMID:  23276932     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Colorectal cancer is one of the leading causes of cancer deaths. At present, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) cetuximab and panitumumab and anti-vascular endothelial growth factor (VEGF) mAb bevacizumab have been incorporated into treatment paradigms for patients with refractory metastatic colorectal cancer. However, many patients simply do not respond to these treatments or eventually acquire resistance following a short course therapy. In this article, we review the literature for studies on the expression patterns, prognostic significance and predictive value of HER (also called erbB) family members and other factors for response to therapy with the HER inhibitors in colorectal cancer. We discuss some of the advances, challenges as well as future opportunities for more effective targeting of the HER receptors using a cocktail of HER inhibitors (e.g. dual and pan HER TKIs, monospecific or bispecific antibodies) in combination with other therapeutic interventions.
Authors:
Said Abdullah Khelwatty; Sharadah Essapen; Alan Michael Seddon; Helmout Modjtahedi
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  394-421     Citation Subset:  IM    
Affiliation:
School of Life Sciences, Kingston University London, Kingston-upon-Thames, Surrey KT1 2EE, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Colorectal Neoplasms / drug therapy*,  physiopathology,  secondary
Humans
Prognosis
Quinazolines / therapeutic use
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Receptor, erbB-2 / antagonists & inhibitors*
Receptor, erbB-3 / antagonists & inhibitors
Signal Transduction / drug effects
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/IMC-11F8 monoclonal antibody; 0/Quinazolines; 0/Vascular Endothelial Growth Factor A; 0/panitumumab; 2S9ZZM9Q9V/bevacizumab; EC 2.7.10.1/Receptor Protein-Tyrosine Kinases; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2; EC 2.7.10.1/Receptor, erbB-3; EC 2.7.10.1/receptor tyrosine-protein kinase erbB-4; PQX0D8J21J/cetuximab; S65743JHBS/gefitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanisms of cardioprotection by isoflurane against I/R injury.
Next Document:  T lymphocyte trafficking: molecules and mechanisms.